2021
DOI: 10.34172/apb.2022.025
|View full text |Cite
|
Sign up to set email alerts
|

Exendin-4 as a Versatile Therapeutic Agent for the Amelioration of Diabetic Changes

Abstract: Type 2 diabetes mellitus is a chronic metabolic abnormality leading to microvascular and macrovascular complications. Non-insulin Incretin mimic synthetic peptide exendin-4 was introduced as an anti-diabetic drug which helped diabetic patients with triggering insulin secretion; further researches have revealed an effective role of exendin-4 in treatment of type 2 diabetes mellitus related diseases. Exendin-4 is approximately similar to Glucagon-like peptide, thus it can bind to the glucagon-like peptide-1 rece… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 104 publications
0
5
0
Order By: Relevance
“…Although previous studies had hinted at this correlation [ 126 , 127 ], their investigation aimed to elucidate the molecular link between the two conditions. Exendin-4, a peptide agonist of the glucagon-like peptide receptor recognized for its role in insulin secretion and as a versatile therapeutic agent for diabetes, [ 128 ] was administered to APP/PS1 transgenic mice along with infliximab. This intervention resulted in a notable reduction in hippocampal serine phosphorylation of insuline receptor substrate-1 (IRS-1), an event frequently observed in both diabetes and AD [ 129 ].…”
Section: Evidence In Animal Models Of Alzheimer’s Diseasementioning
confidence: 99%
“…Although previous studies had hinted at this correlation [ 126 , 127 ], their investigation aimed to elucidate the molecular link between the two conditions. Exendin-4, a peptide agonist of the glucagon-like peptide receptor recognized for its role in insulin secretion and as a versatile therapeutic agent for diabetes, [ 128 ] was administered to APP/PS1 transgenic mice along with infliximab. This intervention resulted in a notable reduction in hippocampal serine phosphorylation of insuline receptor substrate-1 (IRS-1), an event frequently observed in both diabetes and AD [ 129 ].…”
Section: Evidence In Animal Models Of Alzheimer’s Diseasementioning
confidence: 99%
“…[70][71][72][73] Differentiation of MSCs into insulinproducing cells requires factors such as fibroblast growth factor (FGF), insulin-like growth factor 1 (IGF-1), and activin-A, which is a dimeric glycoprotein belonging to the transforming family growth factors-𝛽 (TGF-𝛽), a betacellulin protein encoded by the BTC gene on chromosome 4 at the 4q13-q21 locus in humans. [74][75][76][77][78][79] ). Paracrine factors secreted by MSCs have a variety of therapeutic effects, including anti-inflammatory, immunomodulatory, and tissue regenerative effects.…”
Section: Mechanism Of Differentiation Of Mscsmentioning
confidence: 99%
“…[ 70–73 ] Differentiation of MSCs into insulin‐producing cells requires factors such as fibroblast growth factor (FGF), insulin‐like growth factor 1 (IGF‐1), and activin‐A, which is a dimeric glycoprotein belonging to the transforming family growth factors‐β (TGF‐β), a betacellulin protein encoded by the BTC gene on chromosome 4 at the 4q13‐q21 locus in humans. [ 74–79 ]…”
Section: Mechanism Of Differentiation Of Mscsmentioning
confidence: 99%
“…Production of neural 5-HT is under the control of a different regulatory gene than peripheral 5-HT, and 5-HT cannot readily cross the blood-brain barrier. GLP-1 has recently gained popularity as a therapeutic to combat type 2 diabetes (47)(48)(49), which is produced centrally by the PPGNs of the NTS (and to a lesser extent the OB). 5-HT has been shown to differentially modulate PPGNs via 5-HT 1A and 5-HT 2C receptors, respectively (24).…”
Section: Figure 2)mentioning
confidence: 99%